A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma
Background & Aims Preclinical studies have demonstrated the additive effect of rapamycin with bevacizumab for hepatocellular carcinoma treatment. We conducted a Phase 1 study to evaluate the safety and pharmacokinetics of the combination in patients with hepatocellular carcinoma. Methods...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2013
|
| Online Access: | https://hdl.handle.net/10356/106813 http://hdl.handle.net/10220/17665 http://dx.doi.org/10.1016/j.ejca.2012.11.008 |
| _version_ | 1811697079649566720 |
|---|---|
| author | Choo, S. P. Chowbay, B. Ng, Q. S. Thng, C. H. Lim, Cindy. Hartono, Septian. Koh, T. S. Huynh, H. Poon, D. Ang, M. K. Chang, S. Toh, H. C. |
| author2 | School of Electrical and Electronic Engineering |
| author_facet | School of Electrical and Electronic Engineering Choo, S. P. Chowbay, B. Ng, Q. S. Thng, C. H. Lim, Cindy. Hartono, Septian. Koh, T. S. Huynh, H. Poon, D. Ang, M. K. Chang, S. Toh, H. C. |
| author_sort | Choo, S. P. |
| collection | NTU |
| description | Background & Aims
Preclinical studies have demonstrated the additive effect of rapamycin with bevacizumab for hepatocellular carcinoma treatment. We conducted a Phase 1 study to evaluate the safety and pharmacokinetics of the combination in patients with hepatocellular carcinoma.
Methods
Adult participants with advanced hepatocellular carcinoma received intravenous bevacizumab (5mg/kg every 14days) and oral rapamycin (1–6mg/day; 3+3 dose escalation design). Computed tomography assessed tumour response and treatment safety. Pharmacokinetics assessment established rapamycin blood concentrations pre- and post-dose. Dynamic contrast-enhanced computed tomography analysed the tumour region for blood flow, permeability surface area product, fractional intravascular blood volume and extracellular–extravascular volume.
Results
Twenty-four participants were treated. There were two dose limiting toxicities with rapamycin 5mg: grade 3 thrombocytopenia and grade 3 mucositis. The maximally tolerated dose of rapamycin was 4mg. Adverse events (grade 1–2) included hyperglycaemia (83%), thrombocytopenia (75%), fatigue (46%), mucositis (46%), anorexia (42%), diarrhoea (33%) and proteinuria (12.5%).
Of 20 evaluable participants, one reached complete response that lasted 4.5months, two reached partial response, 14 reached stable disease and three had progressive disease. Median overall survival was 9.4months; progression-free survival was 5.5months.
Dose level and steady state area under the concentration time curve for hour zero to infinity of rapamycin correlated inversely with blood flow rate and change in permeability-surface area. After 22days of treatment, there were significant reductions from baseline in blood flow rate, permeability-surface area and fractional intracellular blood volume.
Conclusions
The recommended Phase 2 dose of rapamycin is 4mg in combination with bevacizumab. Evidence of anti-vascular activity was observed together with promising clinical activity. |
| first_indexed | 2024-10-01T07:49:33Z |
| format | Journal Article |
| id | ntu-10356/106813 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T07:49:33Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | ntu-10356/1068132019-12-06T22:18:56Z A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma Choo, S. P. Chowbay, B. Ng, Q. S. Thng, C. H. Lim, Cindy. Hartono, Septian. Koh, T. S. Huynh, H. Poon, D. Ang, M. K. Chang, S. Toh, H. C. School of Electrical and Electronic Engineering Background & Aims Preclinical studies have demonstrated the additive effect of rapamycin with bevacizumab for hepatocellular carcinoma treatment. We conducted a Phase 1 study to evaluate the safety and pharmacokinetics of the combination in patients with hepatocellular carcinoma. Methods Adult participants with advanced hepatocellular carcinoma received intravenous bevacizumab (5mg/kg every 14days) and oral rapamycin (1–6mg/day; 3+3 dose escalation design). Computed tomography assessed tumour response and treatment safety. Pharmacokinetics assessment established rapamycin blood concentrations pre- and post-dose. Dynamic contrast-enhanced computed tomography analysed the tumour region for blood flow, permeability surface area product, fractional intravascular blood volume and extracellular–extravascular volume. Results Twenty-four participants were treated. There were two dose limiting toxicities with rapamycin 5mg: grade 3 thrombocytopenia and grade 3 mucositis. The maximally tolerated dose of rapamycin was 4mg. Adverse events (grade 1–2) included hyperglycaemia (83%), thrombocytopenia (75%), fatigue (46%), mucositis (46%), anorexia (42%), diarrhoea (33%) and proteinuria (12.5%). Of 20 evaluable participants, one reached complete response that lasted 4.5months, two reached partial response, 14 reached stable disease and three had progressive disease. Median overall survival was 9.4months; progression-free survival was 5.5months. Dose level and steady state area under the concentration time curve for hour zero to infinity of rapamycin correlated inversely with blood flow rate and change in permeability-surface area. After 22days of treatment, there were significant reductions from baseline in blood flow rate, permeability-surface area and fractional intracellular blood volume. Conclusions The recommended Phase 2 dose of rapamycin is 4mg in combination with bevacizumab. Evidence of anti-vascular activity was observed together with promising clinical activity. 2013-11-15T05:12:17Z 2019-12-06T22:18:56Z 2013-11-15T05:12:17Z 2019-12-06T22:18:56Z 2013 2013 Journal Article Choo, S. P., Chowbay, B., Ng, Q. S., Thng, C. H., Lim, C., Hartono, S., et al. (2013). A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. European journal of cancer, 49(5), 999-1008. 0959-8049 https://hdl.handle.net/10356/106813 http://hdl.handle.net/10220/17665 http://dx.doi.org/10.1016/j.ejca.2012.11.008 en European journal of cancer |
| spellingShingle | Choo, S. P. Chowbay, B. Ng, Q. S. Thng, C. H. Lim, Cindy. Hartono, Septian. Koh, T. S. Huynh, H. Poon, D. Ang, M. K. Chang, S. Toh, H. C. A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| title | A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| title_full | A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| title_fullStr | A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| title_full_unstemmed | A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| title_short | A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| title_sort | phase 1 dose finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma |
| url | https://hdl.handle.net/10356/106813 http://hdl.handle.net/10220/17665 http://dx.doi.org/10.1016/j.ejca.2012.11.008 |
| work_keys_str_mv | AT choosp aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT chowbayb aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT ngqs aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT thngch aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT limcindy aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT hartonoseptian aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT kohts aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT huynhh aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT poond aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT angmk aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT changs aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT tohhc aphase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT choosp phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT chowbayb phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT ngqs phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT thngch phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT limcindy phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT hartonoseptian phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT kohts phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT huynhh phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT poond phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT angmk phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT changs phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma AT tohhc phase1dosefindingandpharmacodynamicstudyofrapamycinincombinationwithbevacizumabinpatientswithunresectablehepatocellularcarcinoma |